U.S. Markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,783.90
    +21.20 (+1.20%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    47,971.79
    -8,227.68 (-14.64%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

TRACON Pharma, Eucure Join Forces To Develop CTLA-4 Antibody For Oncology Indications

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • TRACON Pharmaceuticals Inc (NASDAQ: TCON) entered into a collaborative partnership agreement with Eucure Biopharma, a subsidiary of Biocytogen Pharmaceuticals (Beijing) Co Ltd, for the R&D of YH001.

  • Specific deal terms were not disclosed.

  • YH001 is an IgG1 antibody against CTLA-4 with enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effector functions, for development in multiple oncology indications, including soft tissue sarcoma, in North America.

  • Under the terms of the agreement, TRACON will be responsible for the clinical development and commercialization of YH001 in North America.

  • The majority of the development activities are expected to occur in the U.S.

  • TRACON will bear the costs of clinical trials, and Eucure Biopharma will supply YH001.

  • TRACON will be responsible for commercializing YH001 in multiple oncology indications in North America and will owe Eucure Biopharma escalating double-digit royalties on net sales.

  • Price Action: TCON shares are up 2.12% at $3.85 during the market session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.